National Eye Institute-supported Clinical Trials Currently Recruiting Patients

National Eye lnstitute..supported Clinical Trials Currently Recruiting Patients As a service to readers, their patients, and the National Eye Institute, Ophthalmology prints monthly a list of National Eye Institutesponsored clinical trials that are still recruiting patients. By consulting these pages, clinicians can find the information they need to refer patients to appropriate clinical centers. For more information on these and other NEI studies see the 1993 edition of Clinical Trials Supported by the National Eye Institute. For a detailed description please call the Study Center Office or see Clinical Trials. Age-Related Eye Disease Study (Will estimate progression rates and risk factors for age-related macular degeneration [AMD] and cataract.) Recruiting men and women, 55 to 78 years old, whose macular status ranges from no evidence of AMD in either eye to relatively severe disease with vision loss in one eye but good vision in the fellow eye. Study Center Office 301-496-6583 Clinical Centers: Georgia (Atlanta); Illinois (Harvey); Maryland (Baltimore, Bethesda); Massachusetts (Boston); Michigan (Royal Oak); New York (Albany); Oregon (Portland); Pennsylvania (Pittsburgh); Wisconsin (Madison). Collaborative Ocular Melanoma Study (To determine whether enucleation or radiation therapy is more likely to prolong survival of patients with medium-sized tumors; to determine whether preoperative radiation prolongs life for patients when eyes with large tumors are enucleated; and to assess the potential life-preserving as well as sight-preserving role of radiation therapy.) Recruiting men and women at least 21 years old who have primary choroidal melanoma in only one eye and no evidence of metastatic disease. Study Center Office 1-800-553-9114 Clinical Centers: Arizona (Tucson); California (Los Angeles, Panorama City, San Francisco); Colorado (Denver); Florida (Miami, Tampa); Georgia (Atlanta); Illinois (Chicago); Indiana (Indianapolis); Iowa (Iowa City); Louisiana (New Orleans); Maryland (Baltimore); Massachusetts (Boston); Michigan (Ann Arbor, Royal Oak); Minnesota (Rochester); Missouri (St. Louis); New York (Manhasset, New York); North Carolina (Durham); Ohio (Beachwood, Cleveland, Columbus); Oklahoma (Oklahoma City); Oregon (Portland); Pennsylvania (Philadelphia, Pittsburgh); Texas (Dallas, Houston, San Antonio, Temple); Virginia (Charlottesville); Washington (Seattle); Wisconsin (Madison, Milwaukee); Canada (Montreal, Toronto). Endophthalmitis Vitrectomy Study (To evaluate the role of pars plana vitrectomy and intravenous antibiotics in treatment of postoperative endophthalmitis.) Recruiting men and women with signs/symptoms of bacterial endophthalmitis in an eye that had cataract surgery or lens implantation within 6 wks of onset of infection. VA must be 20/50 or worse; light perception or better. Study Center Office 412-683-5300 Clinical Centers: California (La Jolla, Los Angeles); Washington, DC; Florida (Clearwater, Gainesville, Tampa); Georgia (Atlanta); Illinois (Harvey); Kentucky (Louisville); Maryland (Baltimore, Chevy Chase); Massachusetts (Boston); Michigan (Ann Arbor, Royal Oak); Minnesota (Edina, Minneapolis); New Jersey (Edison); Ohio (Beachwood, Columbus, Toledo); Oklahoma (Oklahoma City); Pennsylvania (Hershey, Philadelphia, Pittsburgh); Texas (Houston); Wisconsin (Milwaukee). Herpetic Eye Disease Study II (To evaluate the efficacy of oral acyclovir in preventing recurrent herpetic eye disease; to evaluate the efficacy of oral acyclovir in preventing progression of acute epithelial keratitis to stromal keratitis and iridocyclitis; and to investigate the impact of psychological, environmental, and biological factors on herpes simplex virus recurrence.) Re-

792

cruiting males and females at least 12 years old with acute or recurrent herpetic eye disease. Study Center Office 415-476-2658 Clinical Centers: Georgia (Atlanta); Illinois (Chicago); Louisiana (New Orleans); Michigan (Ann Arbor); New York (New York); Pennsylvania (Philadelphia); Texas (Houston); Wisconsin (Milwaukee). Ischemic Optic Neuropathy Decompression Trial (To assess the safety and efficacy of optic nerve sheath decompression surgery for non-arteritic ischemic optic neuropathy.) Recruiting men and women with acute non-arteritic ischemic optic neuropathy who are at least 50 years old and within 10 days of the onset of visual symptoms. Best-corrected visual acuity in the study eye must be equal to or worse than 20/64. Study Center Office 410-328-8159 Clinical Centers: California (Los Angeles, San Francisco); Florida (Gainesville); Georgia (Atlanta); Illinois (Chicago); Kentucky (Lexington); Maryland (Baltimore); Michigan (Ann Arbor, Detroit, East Lansing, Royal Oak); Minnesota (Rochester); Missouri (Columbia, St. Louis); New York (Syracuse); North Carolina (Charlotte); Ohio (Cleveland, Columbus); Pennsylvania (Pittsburgh); South Carolina (Columbia); Texas (Houston); Utah (Salt Lake City); Virginia (Charlottesville, Richmond); West Virginia (Morgantown). Studies of the Ocular Complications of AIDS II: CMV Retinitis Retreatment Trial (To compare the safety and efficacy of three therapeutic regimens for AIDS-related retinitis in patients who were treated with foscarnet or ganciclovir and whose retinitis progressed or reoccurred.) Recruiting men and women with recurrent AIDS-related CMV retinitis. Study Center Office 410-955-1966 Clinical Centers: California (La Jolla, Los Angeles, San Francisco); Florida (Miami); Illinois (Chicago); Louisiana (New Orleans); Maryland (Baltimore); New York (New York); Texas (Houston).

INTRAMURAL STUDY Placement of Ganciclovir Insert for CMV Retinitis (To assess the efficacy and safety of ganciclovir delivered directly into the eye through a small, surgically implanted device as a treatment for CMV retinitis.) Recruiting men and women with CMV retinitis that has not affected central vision; patients must not have been previously treated with ganciclovir or foscarnet. Study Center Contacts Susan Mellow, RN Warren Grant Magnuson Clinical Center Bethesda, Maryland 301-496-3123 I :00-4:00 p.m. Linda Poellnitz University of Texas Southwestern at Dallas Dallas, Texas 214-688-3838